Q&A: Nathan Tinker, New York Biotechnology Association
While at the 2014 New York BIO Conference (NYBIO), Applied Clinical Trials‘ Moe Alsumidaie spoke to Nathan Tinker, Executive Director at the New York Biotechnology Association.
Nathan Tinker
While at the 2014 New York BIO Conference (NYBIO), Applied Clinical Trials‘ Moe Alsumidaie spoke to Nathan Tinker, Executive Director at the New York Biotechnology Association, about challenges in early phase development.
The New York Biotechnology Association is dedicated to the development and growth of New York State-based bioscience related industries and institutions.
Moe Alsumidaie: How is NYBIO Changing?Nathan Tinker: When the organization was founded over 25 years ago, it was a biotechnology peer planning organization. However, it was clear that biopharmaceutical companies rapidly became a part of the equation. In the last two years, we have seen growth in the agricultural sciences industry, medical devices, combination therapies. Additionally, hospitals, clinicians, and payers/providers became more engaged in early-stage R&D development. Our objective is to take advantage of this culture and fully encompass what BIO has become on both national and policy fronts.
For the rest of the interview, click here.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
